These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 1532501)

  • 1. State of the art therapy of mycosis fungoides and Sézary syndrome.
    Kemme DJ; Bunn PA
    Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycosis fungoides and the Sézary syndrome.
    Kim YH; Hoppe RT
    Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for mycosis fungoides and the Sézary syndrome.
    Rosen ST; Foss FM
    Hematol Oncol Clin North Am; 1995 Oct; 9(5):1109-16. PubMed ID: 8522487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.
    Molin L; Thomsen K; Volden G; Aronsson A; Hammar H; Hellbe L; Wantzin GL; Roupe G
    Acta Derm Venereol; 1987; 67(3):232-6. PubMed ID: 2442936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Zic JA
    Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin directed therapy for mycosis fungoides: a review.
    Berthelot C; Rivera A; Duvic M
    J Drugs Dermatol; 2008 Jul; 7(7):655-66. PubMed ID: 18664158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycosis fungoides: pathophysiology and emerging therapies.
    Duvic M; Foss FM
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S21-8. PubMed ID: 18086343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
    Janiga J; Kentley J; Nabhan C; Abdulla F
    Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
    Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
    J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
    Schappell DL; Alper JC; McDonald CJ
    Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
    Dummer R; Foss F; Dreno B; Bagot M
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
    Dugas-Breit S; Schulze HJ; Hallermann C
    J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome.
    Tsirigotis P; Pappa V; Papageorgiou S; Kapsimali V; Giannopoulou V; Kaitsa I; Girkas K; Papageorgiou E; Stavrianeas N; Economopoulos T; Dervenoulas J
    Br J Dermatol; 2007 Jun; 156(6):1379-81. PubMed ID: 17459033
    [No Abstract]   [Full Text] [Related]  

  • 15. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
    Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
    J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of mycosis fungoides.
    Mestel DS; Beyer M; Steinhoff M; Sterry W; Assaf C
    G Ital Dermatol Venereol; 2008 Dec; 143(6):395-408. PubMed ID: 19169212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current therapy concepts in cutaneous T-cell lymphomas].
    Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G
    Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group.
    Thomsen K; Molin L; Volden G; Lange Wantzin G; Hellbe L
    Acta Derm Venereol; 1984; 64(6):563-6. PubMed ID: 6084938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
    Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
    J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
    Whittaker SJ; Foss FM
    Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.